RxDoctor Payments Data

Ashleigh Reimann

Family · Birmingham, ALNPI 1154738771

Payments from drug & device makers

$6,711in general payments, 2019–2025

Across 319 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Mallinckrodt Hospital Products Inc.$887
  • AstraZeneca$610
  • Boehringer Ingelheim$593
  • Grifols USA, LLC$451
  • Actelion Pharmaceuticals US, Inc.$360
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$6,61199%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,711 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$21,191
Medicare patients
170
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol67$32,004
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$29,878
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$24,487
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$19,584
Spiriva RespimatTiotropium Bromide18$16,232
SymbicortBudesonide/Formoterol Fumarate19$7,576
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$3,162
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$3,092
Albuterol Sulfate HfaAlbuterol Sulfate97$2,555
Ventolin HfaAlbuterol Sulfate24$1,329
Montelukast Sodium64$772
Ipratropium Bromide15$664
Fluticasone Propionate36$600
Azelastine Hcl11$233
Prednisone23$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$1,280$81,466154 claims
AstraZenecaBreztri Aerosphere, Symbicort$610$32,06255 claims
Boehringer IngelheimSpiriva Respimat$593$16,23218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.

Other family in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →